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ABSTRACT 16 
Necrotic enteritis in broilers is caused by Clostridium perfringens type A strains that produce the 17 
NetB toxin. It is one of the diseases that gained worldwide importance the last decade. Prevention 18 
strategies include avoiding predisposing factors, such as coccidiosis, and in-feed supplementation of a 19 
variety of feed additives. For protection against a toxin-producing bacterium, vaccination with 20 
modified toxin or other secreted immunogenic proteins seems a logical preventive tool. Formalin 21 
inactivated crude supernatant has been used for vaccination initially. Recently, several studies have 22 
been carried out to identify the most important immunogenic and protective proteins that can be used 23 
for vaccination. These include the NetB toxin, but also multiple other proteins. There is evidence that 24 
immunization with single proteins is not protective against severe challenge and that combinations of 25 
different antigens are needed. Most published studies used multiple dosage vaccination regimens that 26 
are not relevant for practical use in the broiler industry. Single vaccination regimens at day-old seem 27 
to be non-protective. This review describes the history of vaccination strategies against necrotic 28 
enteritis in broilers and gives an update on future vaccination strategies that are applicable in the field. 29 
These may include breeder hen vaccination, in ovo vaccination and live attenuated vectors to be used 30 
in feed or in drinking water. 31 
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1. Introduction 35 
 36 
Gastrointestinal diseases in broilers have become increasingly important worldwide for multiple reasons. 37 
First, high-density floor-housing ensures easy spread of excreted gut pathogens (Guardia et al., 2011). 38 
Secondly, due to improvements in genetics, broilers have become amazingly capable to convert feed 39 
energy in body weight and the gastro-intestinal tract of these animals is highly efficient in absorption of 40 
nutrients. Gut micro-organisms play an essential role in degradation of feed components, and there is a 41 
complex interplay between gut bacteria and the gastro-intestinal mucosa, either or not beneficial or 42 
harmful for the host, depending on the microbial composition. Nutritionists are constantly looking at 43 
improving the limits of digestibility and this has caused gut health problems related to bacterial 44 
overgrowth, or in other words, an excess of feed nutrients in the gut that are used by harmful micro-45 
organisms, such as Clostridium perfringens (C. perfringens). Thirdly, there is public and governmental 46 
pressure to reduce the use of antibiotics in broilers. The traditional antimicrobial growth promotors 47 
(AGPs), used to improve feed conversion ratios and body weight gain, have been banned in the European 48 
Union. Also in other countries, consumers put pressure on the poultry industry to rear animals without 49 
AGPs. Therapeutic antibiotics are also widely used for preventive and curative interventions against 50 
gastro-intestinal pathologies and especially the preventive use is heavily disputed. For all these reasons, 51 
some microbial gut pathogens have emerged in broilers, and C. perfringens is one of these. This pathogen 52 
clearly benefits from high energy diets supporting its fast growth. It is also clear that the use of AGPs in 53 
feed protected broilers from disease caused by C. perfringens (Johansson et al., 2004; Martel et al., 2004; 54 
Lanckriet et al., 2010a).  55 
C. perfringens is a gram-positive spore-forming bacterium causing necrotic enteritis, of which the typical 56 
hallmark is small intestinal necrosis. While the acute clinical form is associated  with a sudden increase in 57 
flock mortality at an average age of 3 to 4 weeks,  the subclinical form leads to damage to the intestinal 58 
mucosa resulting in decreased digestion and absorption, reduced weight gain and increased feed 59 
conversion ratio (Ficken & Wages, 1997; Kaldhusdal, et al., 2001). Estimates of the prevalence of 60 
necrotic enteritis vary widely because of the unnoticeable subclinical form, but percentages as high as 61 
40% have been reported (Kaldhusdal et al., 2001). The economic impact is thus high. The disease is 62 
triggered by a variety of predisposing factors. Damage to the intestinal mucosa is an important 63 
predisposing factor, and especially coccidiosis co-infection is known to have a high impact (Elwinger et 64 
al., 1992; Williams, 2005).  Also the feed composition is of importance, and high-protein and high-non-65 
starch polysaccharide containing diets are predisposing (Branton et al., 1987; Riddell & Kong, 1992; 66 
Branton et al., 1997; Gholamiandehkordi et al., 2007; Van Immerseel et al., 2009).  67 
Therapeutic antibiotics, such as amoxicillin and tylosin, are often used to (prevent and) control necrotic 68 
enteritis (Hermans & Morgan, 2007). The use of antibiotics is no longer considered as an optimal strategy 69 
for keeping gut health problems under control because of issues related to antibiotic resistance. Therefore, 70 
better farm management, including biosecurity measures and optimization of feed quality have gained 71 
interest. Additionally,  feed additives, including organic acids, essential oils and prebiotics, have  been 72 
tested in animal models and shown to be, at least partially,  able to control necrotic enteritis  (Lensing et 73 
al., 2010a; Timbermont et al., 2010; Jerzsele et al., 2012). For a disease caused by a toxin producing 74 
bacterium, it seems logical however to explore whether vaccines can be developed, either or not based on 75 
the causative toxins. Much work has been done in recent years in this area and proteins and toxins have 76 
been tested as vaccine candidates. In addition, the use of live vectors is under investigation and studies are 77 
being carried out on practical strategies for vaccination in the field.  A major question is how birds can be 78 
protected by vaccination in the limited time span of 3 to 4 weeks before the lesions mostly develop. The 79 
disease thus mostly develops at an age when maternal antibodies have declined. In addition, vaccination of 80 
young broilers is hampered by the immature immune system and problems related to mass vaccination (ie. 81 
the inability to boost immunity). Solutions are under way to solve these issues. In the current paper an 82 
overview is given on the information available of the use of potential vaccine preparations, and a critical 83 
view is presented on the practical implementation of vaccination to protect broilers against necrotic 84 
enteritis.   85 
 86 
2. Antibody responses to C. perfringens antigens 87 
 88 
The immune response to C. perfringens infection, including immune recognition of the pathogen and its 89 
secreted proteins and toxins, is still poorly understood. In addition, there are uncertainties about the type 90 
of antibodies (IgA, IgY) and the specificity of the antibodies (antigen to which the antibodies are directed 91 
to) that are associated with protection. Infection takes place in the small intestines where the pathogen 92 
makes contact with the mucosal surface. The enteric immune system of neonatal broilers is poorly 93 
developed and matures rapidly up to 4-6 weeks post hatch (Mast & Goddeeris, 1999). Generally, adaptive 94 
immune defense at the mucosal surface is mediated by initiation of lymphocyte activation and local 95 
secretion of IgA (Muir et al., 2000; Sharma, 1999). Mucosal IgY may be important in protection against 96 
necrotic enteritis, since it is the major transferred maternal antibody and it plays an essential role in 97 
protection of young chickens against other pathogens. Maternal antibody declines by about 3 weeks of 98 
age, which may explain why broiler chickens mostly develop necrotic enteritis around that time point 99 
(Ulmer-Franco et al., 2012).  100 
It was shown that the level of specific maternal antibodies against alpha toxin was higher in day-old 101 
chickens from older hens than in the progenies from younger hens.  Broilers with high titers of specific 102 
maternal antibodies (IgY) against alpha toxin were shown to have lower mortality (Heier, Lovland, 103 
Soleim, Kaldhusdal, & Jarp, 2001). When naturally infected chickens are able to develop an antibody 104 
response, this response may have a value for protection against the disease (Lovland et al., 2003). Levels 105 
of antibodies (IgY) against NetB and alpha toxin were significantly higher in apparently healthy chickens 106 
compared to chickens with clinical necrotic enteritis. This suggests that these antibodies may play a role in 107 
the protection against necrotic enteritis (Lee et al., 2012).  108 
In several vaccination studies a mucosal IgA response against alpha toxin, NetB and other immunogenic 109 
proteins was reported in chickens (partially) protected against necrotic enteritis (Kulkarni et al., 2007; 110 
Kulkarni et al., 2010; Jang et al., 2012). However, in intestinal washings from experimentally infected 111 
birds only weak reactivity of mucosal IgA against proteins of C. perfringens was found. This might 112 
indicate that a serum IgY response plays a more important role in immunity against necrotic enteritis than 113 
mucosal IgA. After systemic immunization with recombinant immunogenic proteins, serum IgY still 114 
reaches the mucosal surface under inflammatory conditions caused by C. perfringens (Williams, 2005; 115 
Kulkarni et al., 2007; Kulkarni et al., 2010). 116 
 117 
3. An overview of vaccination studies against necrotic enteritis 118 
 119 
There are various ways to deliver antigens to chickens for immunization purposes. Potential bacterial 120 
vaccines can be based on live (attenuated) organisms or killed (inactive) organisms.  Live (attenuated) 121 
vaccine strains may be superior because they often have the ability to induce a stronger and longer 122 
immune response and can be administered orally, but there are some safety concerns (Witter & Hunt, 123 
1994; Plotkin & Plotkin, 2011; Rappuoli et al., 2011). For a toxin producing bacterium, however, it seems 124 
logical that culture supernatants or toxin-based formulations are used, ideally in inactivated form while 125 
preserving antigenicity. Formalin inactivation and genetically engineered inactive toxin variants are an 126 
option, as well as the delivery of immunogenic non-toxin proteins. Also DNA vaccines that express 127 
Clostridium toxins have been tested as vaccine candidates  (Saikh et al., 1998; Gardiner et al., 2009; Li et 128 
al. 2011; Jin et al., 2013). 129 
 130 
3.1. Live attenuated vaccines   131 
 132 
The principle that previous infections with C. perfringens strains induce protection against challenge was 133 
proven by Thompson et al. (2006). These authors orally administered virulent strains to 15 day old broiler 134 
chickens during 5 consecutive days, followed by treatment with bacitracin for nine days to clear the 135 
virulent strains. An oral challenge with virulent strain C. perfringens CP4 resulted in significantly fewer 136 
chickens with lesions (mean lesion score 0.13 instead of 2.09 in the non-immunized group). These data 137 
show the potential of vaccination with live strains, but a major issue with live vaccines is the trade-off 138 
between attenuation and protection. Indeed, live strains should be attenuated without losing the ability to 139 
protect against disease. When an avirulent strain was used for oral immunization using the same 140 
immunization-infection protocol, no protection was conferred. In contrast, an alpha toxin mutant of the 141 
challenge strain induced partial protection against infection with an isogenic challenge strain, i.e.  a 142 
significant decrease in number of birds with necrotic lesions was observed (Thompson et al., 2006). It 143 
could very well be that residual virulence (under which maybe NetB production) is essential for a live 144 
vaccine strain to be protective.  Indeed, an avirulent strain is not providing protective antigens to the gut 145 
associated lymphoid tissues, and as a consequence not conferring protection. This observation could 146 
hamper the development of live vaccines, as residual virulence is clearly not acceptable. 147 
 148 
3.2.Protein-based vaccines 149 
 150 
Protein-based vaccines are used because they are safer and better characterized as compared to live 151 
vaccines, while they can still be protective (Unnikrishnan et al., 2012). They include toxoids (inactivated 152 
bacterial toxins) and subunit vaccines, often based on virulence factors or secreted toxins (Berzofsky et 153 
al., 2001).   C. perfringens is known to produce many different toxins and proteins. While in some studies 154 
crude culture supernatants (either or not inactivated) were used as vaccines, other vaccination trials were 155 
carried out using inactivated toxins and highly antigenic proteins.  156 
Both non-inactivated supernatant and formaldehyde-inactivated supernatant (crude toxoid) of C. 157 
perfringens have thus been studied as potential vaccines for the prevention of clinical and subclinical 158 
necrotic enteritis with variable success. In a study by Saleh et al. (2011), subcutaneous vaccination of 159 
broilers at an age of 7 and 21 days with C. perfringens type A, type C and combined type A and C crude 160 
toxoids significantly decreased the number of animals developing intestinal lesions. When breeder hens 161 
were vaccinated at 14 and 18 weeks of age with type A and type C crude toxoids and their progeny was 162 
challenge exposed under both field conditions and in a disease model, type C crude toxoid was shown to 163 
better protect than type A crude toxoid (Lovland et al., 2004). The safety and efficacy of a C. perfringens 164 
type A alpha toxoid (Netvax
TM
) was investigated by vaccinating breeder hens intramuscularly at 11 and 18 165 
weeks of age. In this field trial, the progeny from vaccinated hens had a reduced mortality compared to the 166 
progeny from unvaccinated hens (Crouch et al.,  2010). Lanckriet et al. (2010b) compared the non-167 
inactivated supernatant of 8 C. perfringens strains, with different alpha toxin and NetB content, using 168 
subcutaneous vaccination at an age of 3 and 12 days. They showed important variation in the protective 169 
capacity depending on the strain used for supernatant preparation. This suggests that protective immunity 170 
is probably determined by an effective combination of different bacterial immunogens or that the 171 
expression levels of some (one or more) antigens drives protection conferred by vaccination. The strain 172 
used for crude supernatant collection is thus of crucial importance when designing these vaccine types. It 173 
is clear that non-inactivated supernatant always contains a risk because of the presence of active toxins, 174 
and thus crude toxoids are preferred for safety reasons. Formaldehyde is mostly used for inactivating the 175 
activity of proteins in vaccines but can reduce the protective capacity of the vaccine. Mot et al. (2013) 176 
showed that the efficacy of subcutaneous vaccination at the age of 3 and 12 days against necrotic enteritis 177 
using crude supernatant was abolished when the supernatant was formaldehyde inactivated. A logical way 178 
for vaccine development against diseases caused by toxin-producing bacteria is the use of inactivated 179 
toxin preparations. The alpha toxin is the most investigated C. perfringens toxin in terms of vaccine-180 
induced protection, mainly in mouse gangrene models (Stevens et al., 2004; Titball, 2009).  Before the 181 
NetB toxin was identified as the major toxin in necrotic enteritis in broilers, alpha toxin was believed to be 182 
crucial and thus multiple studies used alpha toxin derivatives as vaccine antigen. It has been shown that 183 
broilers with a history of clinical or sub-clinical necrotic enteritis have a natural serum antibody response 184 
to alpha toxin (Heier et al., 2001; Lovland et al., 2003). Cooper et al. (2009) vaccinated broilers 185 
subcutaneously with recombinant alpha toxin at 5 and 15 days of age and showed a decrease in the 186 
number of animals with necrotic enteritis lesions. Jang et al. (2012) vaccinated broilers subcutaneously at 187 
day 1 and day 7 with recombinant alpha toxin and could induce protection against challenge. Using double 188 
and triple intramuscular vaccination regimens (day 7, 14 and 21), Kulkarni et al. (2007) showed that a 189 
prior vaccination with alpha toxoid and a boost with active toxin protected against experimental necrotic 190 
enteritis. A triple vaccination of either alpha toxoid or active toxin offered no protection.  It was suggested 191 
that the failure in protection using the active toxin may have resulted from the toxin activity on immune 192 
cells and the failure of alpha toxoid may be the consequence of loss of conformation of the protein, 193 
resulting in loss of epitopes, as mentioned before.  Although alpha toxin has been shown to play no 194 
primary role in the induction of necrotic enteritis, the antigen can thus still induce a certain level of 195 
protection. It has been shown by Zekarias et al. (2008) that anti-alpha toxin antibodies bind to the cell wall 196 
of the bacterium and suppress the growth of the bacterium in vitro. The binding of the antibodies to the 197 
membrane-bound preprotein might block protein transport channels and hereby inhibit proliferation of the 198 
bacterium.  199 
The discovery of the genetically highly conserved NetB toxin as an essential virulence factor opened new 200 
perspectives for the development of vaccines for the control of necrotic enteritis (Keyburn et al., 2006; 201 
Keyburn et al., 2010a; Keyburn et al., 2010b). After the structure and function of the NetB toxin protein 202 
was analyzed, mutants with reduced cytotoxic activity were designed (Savva et al., 2013; Yan et al., 203 
2013). The mutation of tryptophan to alanine at position 262 (W262A) resulted in a significant reduction 204 
in cytotoxicity to LMH cells and hemolytic activity on red blood cells, and thus showed to be a vaccine 205 
candidate (Savva et al., 2013). Fernandes da Costa SP et al. (2013) vaccinated broilers subcutaneously at 206 
day 3, 9 and 15 with a formaldehyde NetB toxoid or the NetB W262A mutant. Both NetB derived 207 
vaccines were able to induce significant protection against experimental necrotic enteritis. Keyburn et al. 208 
(2013b) immunized chickens subcutaneously with purified recombinant NetB (rNetB), formaldehyde 209 
treated bacterin (consisting of 50:50 sonicated bacterial cells and culture supernatant) and crude toxoid 210 
with or without rNetB supplementation at an age of 7 and 17 days. Chickens vaccinated with rNetB were 211 
significantly protected against experimental necrotic enteritis when challenged with a mild oral dose of 212 
virulent bacteria, but rNetB was not sufficient to protect against a heavy in-feed challenge. Birds 213 
immunized with bacterin and crude toxoid supplemented with rNetB were significantly protected against 214 
moderate and severe in-feed challenge. NetB has thus been shown to have a considerable potential for the 215 
development of vaccines against necrotic enteritis. The best protection was observed when birds were 216 
vaccinated with the crude toxoid or bacterin supplemented with rNetB (Keyburn et al., 2013b). This study 217 
confirmed that NetB alone is not yielding full protection and that supplementation with other antigens 218 
increases the protective response. Keyburn et al. (2013a) also used a non-toxic NetB variant (S254L) for 219 
vaccinating breeder hens (see below).  220 
In addition to toxin-derived protein vaccines, also highly immunodominant proteins can potentially be 221 
used to protect animals against necrotic enteritis by vaccination. As mentioned before, neither single NetB 222 
nor alpha toxin were capable to induce full protection against the development of lesions after 223 
experimental infection. Full protection is probably determined by an effective combination of different 224 
bacterial immunogens (Lanckriet et al., 2010b; Fernandes da Costa SP et al., 2013; Keyburn et al., 225 
2013b). Several purified C. perfringens proteins have been evaluated as potential vaccine candidates. 226 
Several authors identified antigens recognized by post infection sera from chickens immune to necrotic 227 
enteritis. Hypothetical protein (HP), pyruvate:ferredoxin oxidoreductase (PFOR), elongation factor G (EF-228 
G), perfringolysin O, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and a fructose 1,6 229 
biphosphate aldolase (FBA) were identified using post infection serum from chickens immune to virulent 230 
C. perfringens challenge in infection-immunization experiments (Kulkarni et al., 2006). Jiang et al.(2009) 231 
identified the C. perfringens large cytotoxin (TpeL), endo-beta-N-acetylglucosaminidase (Naglu) and 232 
phosphoglyceromutase (Pgm) as dominant antigens using post infection serum from chickens immune to 233 
necrotic enteritis. Elongation factor Tu (EF-Tu) and PFO were identified by reaction with immune sera 234 
from chickens derived from a clinical outbreak. Kulkarni et al. (2007) immunized chickens 235 
intramuscularly two (or three) times at an age of 7, 14 (and 21) days with recombinant proteins alpha-236 
toxin/alpha toxoid, GAPDH, HP, FBA, and PFOR. All the proteins were able to decrease the mean 237 
intestinal lesion score. The degree of protection depended on the severity of the challenge. Alpha toxin, 238 
HP, and PFOR protected significantly against heavy challenge. GAPDH and FBA protected only against 239 
mild challenge. More recently, double subcutaneous vaccination regimens using alpha toxin, NetB toxin, 240 
PFOR and EF-Tu gave similar protection levels after experimental infection (Jang et al., 2012). 241 
Immunization with Naglu and Pgm yielded partial protection after challenge with two different strains. 242 
Again, the protection level decreased when the challenge severity increased (Jiang et al., 2009). All the 243 
above described data thus show that multiple proteins, including derivatives from alpha and NetB toxin, 244 
have potential, and that defined mixtures of these proteins need investigation. 245 
 246 
3.3. Attenuated live vectors expressing C. perfringens proteins 247 
 248 
Attenuated or avirulent bacteria can be used as vehicles for the effective delivery of  vaccine candidates 249 
(Rappuoli et al., 2011). Attenuated Salmonella strains are often used in poultry for the control of 250 
salmonellosis and they can serve as safe and effective oral carrier vaccines to prevent several poultry 251 
diseases by expressing heterologous antigens (Hegazy & Hensel, 2012). Because the attenuation is usually 252 
induced by a deletion mutation in a gene that is essential for the metabolism of the bacterium, the vaccine 253 
carrier strains can not overgrow the immune system of the animal host (Spreng et al., 2006). Zekarias et 254 
al.(2008) evaluated the efficacy of a live recombinant attenuated S. enterica serovar Typhimurium vaccine 255 
strain that delivered the C-terminal domain of the alpha toxin. The vaccine strain was twice administered 256 
orally at 3 and 17 days of age. Thereafter the birds were challenged by oral inoculation and repeated 257 
infection through contaminated feed with a virulent C. perfringens strain. A significant reduction in 258 
number of birds with necrotic lesions was observed.  Kulkarni et al., (2008) showed that the delivery of 259 
FBA and HP using an attenuated S. enterica serovar Typhimurium vaccine vector by the oral route 260 
induced a significant protective immune response. Broilers immunized with the vaccine strain, expressing 261 
PFOR, at day 1 and day 14, however were not significantly protected against necrotic enteritis. The 262 
authors also tested Salmonella strains expressing truncated nontoxic alpha toxoid and truncated HP (tHP). 263 
The alpha toxoid consisted of a region of 162 amino acid residues that included two sections of 264 
immunodominant epitopes as well as regions of weak reactivity. Broiler chickens immunized orally with a 265 
Salmonella strain expressing nontoxic alpha toxoid, at day 1 and day 10 of age, were significantly 266 
protected against moderate experimental necrotic enteritis but not protected against severe challenge, 267 
while chickens immunized with tHP were protected against both moderate and severe challenge (Jiang et 268 
al., 2010; Kulkarni et al., 2010). While Salmonella strains are thus potential vaccine carriers for C. 269 
perfringens proteins, there are other possibilities that, although not yet explored for protection of poultry 270 
against necrotic enteritis, can be of value. The expression of the C-terminal domain of alpha toxin on the 271 
surface of Bacillus subtilis spores was described and shown to be immunogenic in mice (Hoang et al., 272 
2008). Also lactic acid bacteria can be used as vaccine carriers for Clostridium antigens (Robinson et al., 273 
1997; Robinson et al., 2004). B. subtilis and lactic acid bacteria have the advantage to possess a GRAS 274 
(generally recognized as safe) status. The use of live vectors to express C. perfringens proteins in the gut 275 
of broilers thus is a promising approach and deserves further attention, mainly in relation to the optimal 276 
vector to be used and the proteins to be expressed. 277 
 278 
3. The future of vaccine delivery and immunization methods for necrotic enteritis  279 
 280 
In recent years, multiple studies have been carried out on the development of vaccines against necrotic 281 
enteritis. As reviewed in detail above, non-inactivated supernatants, formalin inactivated crude toxoids, 282 
immunogenic proteins and modified toxins have been used in vaccination studies. These have been 283 
administered intramuscularly and subcutaneously, either or not in multiple dosage regimens, or have been 284 
orally delivered by live attenuated vaccine carrier strains. These studies show clearly that multiple 285 
vaccination dosages are necessary for a good immune response and that one parenteral single vaccination, 286 
at day of hatch, offers no protection. Ease of administration of a vaccine is important for making vaccines 287 
acceptable for the poultry industry. Because large populations of animals must be vaccinated, the most 288 
beneficial vaccines are those that can be delivered simultaneously to large numbers of birds with 289 
minimum amount of labor (Sharma, 1999). Broilers are mostly slaughtered around 5 to 7 weeks of age, 290 
and for practical reasons, vaccines are mostly given in the hatchery. Parenteral vaccination of broiler 291 
chickens is theoretically possible at day-of-hatch, but vaccination using live vaccines by spray methods or 292 
drinking water application is easier to apply. Parenteral booster vaccinations are practically impossible for 293 
broilers. It has been shown that booster vaccinations are essential when non-inactivated supernatant and 294 
crude toxoid are used to provide protection, while single immunization seems to have little benefit (Mot et 295 
al., 2013). For protection of broilers against necrotic enteritis, there are thus only few options left. These 296 
are breeder hen vaccination and the use of live bacterial or viral vectors that can deliver antigens in ovo or 297 
during rearing (eg. as feed or drinking water additive, thus oral vaccination), and thus presenting the 298 
antigens for a longer period as compared to parenteral administration of antigens at day-of-hatch. 299 
 300 
3.1. Breeder hen vaccination 301 
 302 
Vaccination of breeder hens is often preferred in the poultry industry. Due to the generation of large 303 
numbers of protected progeny per vaccinated hen, the vaccine cost per chicken is lower as compared to 304 
post-hatch vaccination (Schijns et al., 2008). Passive protection by maternal antibodies in broiler chickens 305 
by breeder hen vaccination could have some limitations with regard to necrotic enteritis. Outbreaks of 306 
necrotic enteritis mostly occur at the age of 3-4 weeks. The immune system of broiler chickens is still 307 
developing at that age and maternal antibodies already have declined (Lovland et al., 2004). Until now,  308 
three studies have reported data on maternal vaccination against necrotic enteritis, two of them using 309 
crude supernatant toxoids and one using rNetB (S254L) either or not in combination with crude toxoid 310 
(Lovland et al., 2004, Crouch et al., 2010, Keyburn et al., 2013a). When breeder hens were vaccinated 311 
intramuscularly at 14 and 18 weeks of age with C. perfringens type A or type C  crude toxoid, an increase 312 
in antibody response to alpha toxin in serum samples of parent hens was shown. In a field trial under 313 
predisposing conditions a partial protection against necrotic enteritis in their progeny was shown (Lovland 314 
et al., 2004). The safety and efficacy of a commercial C. perfringens type A alpha toxoid (Netvax
TM
) was 315 
analyzed by immunizing breeder hens intramuscularly at 11 and 18/19 weeks of age. An increase in 316 
specific alpha toxin IgY antibody response was shown in serum from hens, in the egg yolk from eggs 317 
collected from those hens and in serum from 7-day-old chickens hatched from those eggs (Crouch et al., 318 
2010). In a field trial the progeny (from eggs collected at 27 and 32 weeks) from a group NetVax
TM
-319 
vaccinated hens had a reduced overall mortality as compared to the progeny from an unvaccinated group, 320 
especially at those time points at which necrotic lesions were observed in the progeny from the 321 
unvaccinated group  (Crouch et al., 2010). Recently, a recombinant non-toxic NetB variant (S254L) was 322 
tested in breeder hens, single or combined with crude toxoid (Keyburn et al., 2013a). Hens were 323 
vaccinated subcutaneously at 22, 24 and 26 weeks of age. A significant IgY antibody response against 324 
NetB was detected in serum samples from hens, in the egg yolk of their eggs and in serum from hatched 325 
chickens from vaccinated hens. When the progeny (from eggs collected at 30 weeks) of vaccinated hens 326 
was infected with in-feed C. perfringens at 26 and 27 days of age,  only chickens derived from hens 327 
vaccinated with rNetB (S254L) combined with crude toxoid had a significantly lower lesion score. When 328 
the C. perfringens infection was performed at 14 days of age, chickens derived from hens vaccinated with 329 
single rNetB (S254L) or single crude toxoid were also protected (Keyburn et al., 2013a). The authors 330 
hypothesized that a higher level of specific antibodies at the time of challenge is responsible for the 331 
protection against challenge at earlier age. 332 
 333 
3.2. In ovo vaccination and oral immunization using viral or bacterial vector vaccines  334 
 335 
Chickens can be vaccinated using vector vaccines in ovo or during rearing. Benefits of in ovo vaccination 336 
compared to post-hatch vaccination include earlier immunity, reduction in bird stress, precise and uniform 337 
injection and reduced labor costs (Ricks et al., 1999; Schijns et al., 2008). The vaccine is injected in eggs 338 
during the late embryonation stage, usually at 17-18 days of incubation (Muir et al., 2000). Recombinant 339 
fowl poxvirus (FPV) and herpesvirus of turkey (HVT) replicating viruses are examples of vector vaccines 340 
for in ovo application (Schijns et al., 2008). If a non-replicative vector for C. perfringens antigens would 341 
be injected in ovo, possibly protective antibodies would already decline at the time the diseases occurs. 342 
Also the choice of the adjuvant is important as some adjuvants are known for inducing embryotoxic side 343 
effects (Asif et al., 2004). According to our knowledge there are no studies reporting efficacy of in ovo 344 
vaccination against necrotic enteritis. 345 
Oral immunization of broilers can be done through the feed or drinking water or by spraying the vaccine 346 
on the chickens (Sharma, 1999). These delivery systems are labor- and time-saving and practically 347 
feasible for the broiler industry. Chickens do not always drink regularly in the first days after hatching. In 348 
contrast, spray application may increase the vaccine uptake and lead to a more consistent level of 349 
protection against the pathogen (Atterbury et al., 2010). Orally administered live vaccine strains 350 
expressing C. perfringens antigens and colonizing the intestinal tract of the broilers have been described 351 
(Kulkarni et al., 2008, Zekarias et al., 2008; Kulkarni et al., 2009). The obtained protection depends on 352 
the colonization level and persistence of the vaccine strains. Kulkarni et al. (2008, 2009) immunized 353 
broilers orally at day of hatch and at day 14 with a recombinant S. enterica serovar  Typhimurium strain 354 
expressing truncated proteins of the alpha toxin, FBA, PFOR or HP. They induced a significant protective 355 
immune response but the degree of protection was less than observed when these proteins were 356 
administered intramuscularly in multiple dosages (Kulkarni et al., 2006). Zekarias et al. (2008) inoculated 357 
chickens orally with a S. enterica serovar Typhimurium strain, expressing a nontoxic fragment of alpha 358 
toxin, at day 3 and 13. The antibody response was low, but the immunized chickens had a reduced number 359 
of necrotic enteritis lesions after challenge. The above mentioned studies however used oral gavage of the 360 
vaccine strains. Practical delivery methods, such as in-feed, drinking water or spray application were not 361 
tested yet. Recombinant B. subtilis endospores that express the C-terminal domain of alpha toxin have 362 
been used to vaccinate mice against C. perfringens infection (Hoang et al., 2008). The endospores appear 363 
to provide an adjuvant effect, boosting the immune response to the antigens. The use of these heat-stable 364 
endospores as vaccine delivery agents is a promising idea because they could be incorporated into feed. 365 
This type of bacterial vectors has not been evaluated for necrotic enteritis in broilers. 366 
 367 
3.3. Summary and concluding remarks  368 
 369 
The history of research on necrotic enteritis clearly shows a link between pathogenesis studies and vaccine 370 
development. Before the identification of the major toxin NetB and before the identification of important 371 
immunogenic proteins, formalin-inactivated crude supernatants were tested. The last few years studies 372 
have been carried out using single proteins or combinations of proteins, mostly by parenteral 373 
immunization. A summary is given in table 1. These studies have been important to identify proteins as 374 
vaccine candidates (such as the NetB toxin), and it became clear that combinations of immunogenic 375 
proteins are yielding better protection as compared to single protein immunization. Most of these studies 376 
used multiple dosage parenteral immunization regimes which suffer from lack of practical value for 377 
broilers. Single dosing at day-of-hatch, a possible method that can be used in the field, results in total loss 378 
of protection compared to multiple dosage vaccination. Breeder hen vaccination is an option and several 379 
studies have shown promising results, but the antibody decline in the progeny will decrease the efficacy at 380 
later ages, which may be important for necrotic enteritis which typically occurs at 3 to 4 weeks of age. In 381 
ovo vaccination could be a valuable method, but no data have been reported so far on this strategy. When 382 
immunogenic proteins need to be presented to the immune system for a more prolonged period of time 383 
using a single dosage, live attenuated bacterial (or viral or parasitic) vectors are a potential strategy for the 384 
future. The obtained protection depends on the colonization level and persistence of the live vaccine 385 
strains and the combination and levels of the expressed antigens. The ideal strain would be one that, apart 386 
from inducing immunity and protection, can be added to the feed or drinking water, or sprayed on the day-387 
old chicks in the hatchery. Considering the progress made in recent years, it can be expected that new 388 
protective vaccines will become available in the next few years. 389 
  390 
Table 1: Summary of all studies on vaccination against necrotic enteritis described in the scientific literature. The table shows the route of 
administration, vaccine regimen, antigen, dose, vector (if used), adjuvant, the result of the vaccination study and the literature reference. 
Route of 
Adminis
tration 
Vaccination regimen Vector/Adjuvant Antigen and dose Protection Reference 
IM 
Double (breeder hens week 14 
and 18) 
20% Alhydrogel 
and 0.013% 
thiomersal 
- Type A crude toxoid 
(0.25ml of 1TCP*) 
- Type C crude toxoid 
(0.25ml of 30TCP*) 
- Specific antibody response against alpha 
toxin in breeder hens and their progeny 
- Less mortality in progeny 
(Lovland et 
al., 2004) 
Oral 
Infection-immunization for 5 
consecutive days  
Mixed in feed at 
ratio 2:1 (feed:broth 
culture) 
- Avirulent strain CP5 
- Virulent strain CP1 
- Virulent strain CP4 
- Alpha toxin deficient 
mutants (Cpa
-1
,Cpa
-2
,Cpa
-3
 
and Cpa
-4
) 
- Reduction in chickens with lesions that 
were infection-immunized with CP1, 
CP4, Cpa
-2
 and Cpa
-4
 
(Thompson 
et al., 2006) 
IM 
Double or triple (day 7, 14 
(and 21) 
Quil A 
- Alpha toxin 
- Alpha toxoid 
- HP* 
- FBA* 
- GDP* 
- tPFOR* 
20µg in triple vaccination, 
40µg in double vaccination 
- Serum and intestinal antibody response 
against immunogens 
- Reduction in chickens with lesions 
depending on the severity of challenge 
(Kulkarni et 
al., 2007) 
Oral Double (day 1 and 14) 
Attenuated S. 
enterica serovar 
Typhimurium 
X9241 
- FBA* 
- tPFOR* 
- tHP* 
100µl containing  10
9
 CFU 
- Serum and intestinal antibody response 
against immunogens 
- Reduction in main lesion score and 
increase in body weight gain (FBA and 
tHP) 
(Kulkarni et 
al., 2008) 
Oral 
SC 
Double (day 3 and 13) 
Double (day 3 and 17) 
Triple (day 3, 13 and 35) 
Attenuated S. 
enterica serovar 
Typhimurium 
X8914 
Complete Freunds 
adjuvant (SC) 
- C-terminal domain of 
alpha toxin (rPLC) 
50µg (SC) 
500µl containing  10
9
 CFU 
(oral) 
- Low serum antibody response  
- Reduction in number of chickens with 
lesions 
- Reduction in lesion score 
(Zekarias et 
al., 2008) 
SC Double (day 5 and 15) Quil A 
- Alpha toxin 
20µg 
- Specific serum antibody response against 
alpha toxin 
- Reduction in number of chickens with 
lesions 
(Cooper et 
al., 2009) 
IM 
Double (breeder hens week 11 
and 18-19) 
Light mineral oil 
- Type A crude toxoid 
(0.5ml of 3 TCP*) 
- Specific antibody response against alpha 
toxin in breeder hens and their progeny 
- Lower mortality rate in field trial 
(Crouch et 
al., 2010) 
Oral 
IM 
Double (day 1 and 10) 
Triple (day 1, 10 and 17) 
Attenuated S. 
enterica serovar 
Typhimurium 
X9352 
- Alpha toxoid (region of 
162 amino acid residues) 
- tHP 
100µl containing  10
9
 CFU 
- Serum and intestinal antibody response 
against immunogens 
- Reduction in chickens with lesions 
depending on the severity of challenge 
- Increased body weight 
(Kulkarni et 
al., 2010) 
SC Double (day 3 and 12) Quil A 
- Supernatant of 8 type A 
strains (variable NetB and 
alpha toxin content) 
7 and 70µg 
- Reduction in number of chickens with 
necrotic lesions  
(Lanckrietet 
al., 2010b) 
IM 
Double or triple (day 7, 14 
(and 21) 
Quil A 
- Naglu* 
- Pgm* 
- Serum and intestinal antibody response 
against immunogens 
- Reduction in chickens with lesions 
depending on the severity of challenge 
and challenge strain 
(Jiang et al., 
2009) 
SC Double (day 7 and 21) Unknown 
- Crude toxoid A 
- Crude toxoid C 
- Crude toxoid AC 
- Serum antibody response against 
immunogens 
- Reduction in number of chickens with 
necrotic lesions 
(Saleh et al., 
2011) 
SC Double (day1 and 7) 
Montanide ISA 71 
VG 
- Alpha toxin 
- NetB 
- EF-Tu* 
- PFO* 
50µg 
- Specific serum antibody response against 
NetB and PFO 
- Reduction in lesion score 
 
(Jang et al., 
2012) 
SC 
Single (day1 or 3) 
Double (day 3 and 12) 
Quil A 
- Supernatant NetB positive 
toxin type A strain 
7 and 70µg 
- Reduction in number of chickens with 
necrotic lesions 
- Reduction in lesion score 
(Mot et al., 
2013) 
SC Triple (day 3, 9 and 15) Quil A 
- NetB toxoid 
- NetB (W262A) 
30µg 
- Reduction in number of chickens with 
necrotic lesions 
- Reduction in mean lesion score 
(Fernandes 
da Costa et 
al., 2013) 
SC Double (day 7 and 17) 
60% Montanide 
40% QuilA 
DEAE-dextran 
- NetB 
- Bacterin (50:50 bacterial 
cells and culture 
supernatant) 
- Bacterin + NetB 
50µg 
- Specific serum antibody response against 
NetB 
- Reduction in average lesion score 
depending on the severity of challenge 
(Keyburn et 
al., 2013b) 
SC 
Triple (breeder hens week 22, 
24 and 26) 
60% Montanide 
40% QuilA 
- rNetB(S254L)  
- Crude toxoid (type A, 
- Specific antibody response against NetB 
in breeder hens and progeny 
(Keyburn et 
al., 2013a) 
*TCP (total combining power), (t)HP ((truncated)Hypothetical protein),  FBA (fructose 1,6-biphosphate aldolase), GDP (glyceraldehyde-3-phosphate 
dehydrogenase), (t)PFO(R) ((truncated) pyruvate: ferredoxin oxidoreductase), Naglu (endo-beta-N-acetylglucosaminidase), Pgm (phosphoglyceromutase), EF-Tu 
(elongation factor Tu), CFU (colony forming units) 
SC (subcutaneous), IM (intramuscularly) 
 
 
 
 
DEAE-dextran NetB positive)   
- Crude toxoid (type A, 
NetB positive) + 
rNetB(S254L)  
50µg 
- Reduction in number of chickens with 
necrotic lesions in experimental infection 
trial in progeny 
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